Chronic wounds—diabetic foot ulcers, pressure injuries, vascular insufficiency ulcers—fail to close because cellular and molecular processes that normally drive healing are disrupted. Inflammation persists unchecked, angiogenesis (new blood-vessel growth) stalls, and the wound remains stuck in an early inflammatory phase, never progressing to tissue remodelling and epithelial closure. Exosomes (nano-scale vesicles secreted by cells and carrying proteins, lipids, and genetic material) have emerged as particularly promising for wound therapy because they cross-link immune signalling with fibroblast activation and growth-factor delivery. Umbilical-cord-derived fibroblasts and placental MSCs contribute direct cellular replacement of damaged dermis and subcutaneous layers. The proposed mechanism combines immunomodulation (damping excessive inflammation), stimulation of local vascular growth, and restoration of extracellular matrix architecture.
Chronic wound cell and exosome therapy has been subject to 59 completed trials, with 7 currently enrolling participants. Trials span diabetic foot ulcers (majority), pressure wounds, and mixed aetiology chronic wounds. Closure rates (percentage of wounds achieving full epithelial coverage) in treated cohorts typically range from 55–85% over 8–16 weeks, compared to reported historical control rates of 20–40% for advanced wounds. Exosome-based studies specifically show wound-area reduction averaging 45–70% at 12 weeks. Trial heterogeneity in wound selection, cell dose, and delivery (topical, intradermal injection, or fibrin-scaffold embedding) limits meta-analysis.
Exosome or cellular wound therapy costs €4,500–8,000 for a full treatment course (typically 2–4 applications spaced 2–4 weeks apart). Baseline imaging (photography, planimetry or 3D scanning), wound cleaning, and offtake samples add €800–1,500. Ongoing dressing costs (specialised antimicrobial or growth-factor-enriched dressings often used post-cell delivery) can reach €300–600 per week for 8–12 weeks, significantly extending total investment.
Cell therapy for Chronic Wounds & Ulcers is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Chronic Wounds & Ulcers programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Chronic Wounds & Ulcers overview · Chronic Wounds & Ulcers cost →
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment